Adenocarcinoma of the prostate is the third most common malignancy in men in England and Wales, with over 8000 men dying from the disease every year (OPCS, 1993) . Prostate cancer is unpredictable in its clinical course and biological behaviour. In Europe, over 50% of patients present with locally advanced and/or metastatic disease, amenable to palliation only. In these patients, androgen ablation remains the treatment of choice. However, approximately 15% of men will not respond to hormone manipulation, and the majority of those who do respond will relapse within 3 years. Hormone-refractory disease, while remaining unpredictable, is an untreatable condition resulting in considerable morbidity and mortality. Understanding the mechanisms by which a hormone-sensitive tumour escapes control, and altering these mechanisms to treat affected patients remains a challenge for clinicians and scientists alike.
The accumulation of alterations to both cellular oncogenes and tumour-suppressor genes (TSGs) is associated with tumorigenesis (Bishop, 1991; Marshall, 1991) . The biological behaviour of a tumour and its response to treatment has been shown to be associated with alteration in expression of these oncogenes and TSGs.
In prostate cancer, it is now evident that hormone manipulation achieves its effect through activation of programmed cell death, otherwise known as apoptosis (Kyprianou et al., 1990; Kerr, 1994; Colombel et al., 1992) . Apoptosis is a distinct mode of cell death, which occurs in tissues under normal physiological conditions and in disease, including cancer. A number of genes are responsible for the regulation of apoptosis in disease and in health, including the proto-oncogene bcl-2 (Hockenbury et Bissonnette et al., 1992; Korsmeyer, 1992) and the tumour-suppressor gene p53 (Lane, 1992; Shaw et al., 1992) . Bcl-2 is a protein which protects cells from going into apoptosis. The encoded protein is expressed in the cytoplasm of basal epithelial cells in normal and hyperplastic prostatic tissue. It is also normally expressed in lymphocytes. Hormone-refractory prostatic carcinomas characteristically possess high levels of bcl-2 protein expressed diffusely throughout the tumour. This is also seen in prostatic intraepithelial neoplasia (Colombel et al., 1993) . Bcl-2 overexpression appears to enable the prostate cancer cells to survive in an androgen-deprived environment, and to confer resistance to androgen withdrawal therapy. An untreated prostatic carcinoma with a high proportion of bcl-2-positive cells may, therefore, possess an inherent ability to become hormone refractory as these cells are protected from apoptosis following androgen ablation.
Nuclear accumulation of p53 protein has been shown to be strongly associated with p53 mutations. Wild-type p53 is involved in regulation of cellular proliferation by inducing apoptosis in response to DNA damage, whereas p53 in its mutant form is not able to mediate this effect. A significant proportion of primary human prostatic carcinoma show increased p53 nuclear protein accumulation, which appears to correlate with androgen independence (Navone et al., 1993; Aprikian et al., 1994) .
Based on the evidence that bcl-2 and p53 serve, respectively, a repressor and effector function of a common cell death pathway, the aim of this study was Men with apparently localised disease were treated by watchful waiting, radical prostatectomy or external beam irradiation. Untreated patients who progressed or those who had radiation therapy and relapsed, received secondary androgen ablation. The follow-up period ranged from 17 to 56 months (median 30 months). Failure to respond to treatment was measured according to the following objective and subjective criteria: (1) less than 50% reduction in serum PSA levels measured at diagnosis; (2) lack of significant alteration in tumour bulk and consistency by digital rectal examination (DRE) and transrectal ultrasonography; and (3) persistent or worsening symptoms directly related to prostate cancer. Progression was defined by one or more of the following observations: (1) a rising serum PSA by at least 50% after initial reduction; (2) new skeletal pain related to metastases as shown by isotope bone scanning; and (3) significant alteration in the primary tumour on DRE.
Immunohistochemistry and frequency of apoptotic bodies Sections (4 gim) were cut from formalin-fixed paraffinembedded blocks. These were picked up on APES-coated slides, and dried at 60°C for 1 h. Antigen retrieval was carried out in an Energy Beam Sciences H2500 microwave processor. Sections were heated to 95°C in 0.1 M citrate buffer, pH 7.6, and held at this temperature for 20 min before immunostaining. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxidase for 10 min, while other non-specific activity was reduced by incubation in normal goat serum for a further 10 min. A standard streptavidin-biotin complex (DAKO Duet) method was used with sections incubated in optimally diluted primary antisera overnight at 4°C. Both primary antibodies were supplied by DAKO. The anti-p53 (Searle et al., 1982) . Areas of wellpreserved tumour corresponding to positive staining for p53 and/or bcl-2 were assessed. An eyepiece graticule was used to define the area selected for counting. All interphase tumour nuclei and apoptotic bodies in the field were counted. The Immunostaining and apoptotic index (AI) Thirty-seven of the 77 cancers (48%) showed cytoplasmic staining for bcl-2 ( Figure Ib) (+, n= 17; + +, n= 14; + + +, n = 6). Twenty-seven of these 37 patients were treated with hormone manipulation and 20 (74%) showed hormone resistance (P=0.0128), either initially (n=5) or through escape (n= 15). Twenty-three of 77 men (29.8%) showed strong nuclear staining for p53 (Figure la ) (+, n=3; + +, n=1l; +++, n=9). Of those, 21 were treated with hormones and 14 (66.6%) were hormone resistant (P=0.0012) initially (n=4), or showed progression (n=12). Seventeen patients showed both bcl-2 overexpression and p53 nuclear accumulation, 16 of whom were hormonally manipulated, with 13 (81.3%) having hormone-resistant disease (P< 0.000 1), at the onset of treatment (n = 4), or by relapse (n = 9). Figures 2-4 illustrate the distribution of bcl-2/p53 immunostaining in patients undergoing hormonal therapy and their response to treatment. There were no statistically significant differences between different groups of patients who expressed bcl-2 and/or p53 in terms of serum PSA, Gleason scores, tumour stage and response to radiotherapy (data not shown). In the 51 cancer patients assessed for frequency of apoptotic bodies, Al ranged from 0.5 to 24.5 (mean 2.1) and showed a statistically significant correlation with high tumour grade (P<0.001). In men with BPH, Al ranged from 0-0.5 (mean 0.3). There was no significant correlation between Al and immunostaining for either p53 and/or bcl-2 proteins. Discussion p53 protein accumulation and bcl-2 overexpression have been investigated independently in a large number of different malignancies. In prostate cancer, p53 nuclear staining appears to be present in approximately 20% of tumours (Navone et al., 1993; Visakorpi et al., 1992; Mellon et al., 1992) with occasional discrepancies, often attributed to differences in antibodies used, the dilutions of these antibodies, fixation and processing of the tissues, stage and grade of the tumours investigated and finally, interpretation of the staining patterns (Fisher et al., 1994) . Several reports also confirm that nuclear p53 accumulation correlates with hormone-resistant and aggressive disease (Navone et al., 1993; Hamdy et al., 1993; Aprikian et al., 1994; Myers et al., 1994) . Two further developments have heightened the interest in p53 and its relationship with aggressive prostate cancer. Firstly, the regulating effect of wild-type p53 on apoptosis, and secondly, the finding that tumour regression in prostate cancer following hormone manipulation is largely mediated by programmed cell death (Kyprianou et al., 1990) researchers to investigate other possible mechanisms by which apoptosis could be deregulated in prostate cancer. resulting in progression and hormonal escape. which to date. is an incurable condition. bcl-2 is an oncogene that prolongs cell viability by preventing and overriding programmed cell death mechanisms. bcl-2 overexpression has been demonstrated in hormone-independent prostate cancer in a number of studies. In particular. McDonnell et al. (1992) have found a strong correlation between bcl-2 overexpression by immunohistochemistry and progression of prostate cancer from androgen dependence to hormone resistance in humans. A more recent study by Raffo et al. (1995) demonstrated that bcl-2 overexpression protected prostate cancer cell lines (LNCaP) against apoptotic stimuli in vitro. and enabled the cells to form tumours in castrated male nude mice in vivo. supporting the hypothesis that bcl-2 may be an important factor in the development of hormone-resistant disease. In contrast with prostate cancer, several studies of bcl-2 in other malignancies including colorectal. breast and lung cancer have shown a correlation between bcl-2 protein expression and favourable outcome (Ofner et al.. 1995 : Pezzella et al.. 1993 : Leek et al.. 1994 ). There is. however. a growing body of evidence linking bcl-2 and p53 interaction with regulation of a common cell death pathway. Observations have been made that bcl-2 is able to block p53-associated apoptosis in transformed cell lines. In high-grade B lymphomas Pin's et al. (1994) have demonstrated that simultaneous expression of bcl-2 and p53 protein was associated with poorer prognosis than p53 accumulation alone. Manrn et al. (1994) also found that bcl-2 and p53 may act as potential regulators of a common apoptotic pathway in lymphomagenesis. and demonstrated that overexpressed bcl-2 suppressed wild-type p53-associated apoptosis folloWing ;-irradiation. Furthermore. Haldar et al. (1994) have demonstrated a possible novel mechanism for p53-induced apoptosis through downregulation of bcl-2. In prostate cancer. the relevance of this phenomenon remains controversial. A recent report by Berges et al. (1993) suggests that p53 gene expression is not required to mediate programmed cell death in androgendeprived prostatic glandular epithelial cells. and a further study showed that in rat androgen-sensitive prostatic adenocarcinoma. the biochemical cascade leading to apoptosis was not activated by androgen withdrawal. as in the ventral prostate (Branstr6m et al.. 1994 (Huggins and Hodges. 1941) . the mechanisms of hormone resistance in prostate cancer are still poorly understood. Our study has attempted to shed some light on this phenomenon. Despite the many unexplained complexities relating immunostaiing with genetic alterations, our results suggest that the combined detection of p53 protein accumulation and bcl-2 overexpression may be useful in the prediction of hormoneresistant disease in prostate cancer. Ongoing studies at the molecular level may clarify some of the mechanisms controlling hormone dependence of this common. vet unpredictable. malignancy.
